Table 3 Drug-related deaths by selected drugs reported1, Scotland, 1996 - 2009
Year |
Heroin / |
Meth- |
Benzodiazepines |
Cocaine |
Ecstasy |
Amphet- |
Alcohol |
||
---|---|---|---|---|---|---|---|---|---|
Any |
of which: |
Temaz- epam |
|||||||
1996-2000 average |
128 |
74 |
.. |
116 |
47 |
6 |
7 |
.. |
91 |
1996 |
84 |
100 |
.. |
84 |
48 |
3 |
9 |
.. |
87 |
1997 |
74 |
86 |
.. |
93 |
33 |
5 |
2 |
.. |
70 |
1998 |
121 |
64 |
.. |
113 |
58 |
4 |
3 |
.. |
86 |
1999 |
167 |
63 |
.. |
142 |
56 |
12 |
8 |
.. |
89 |
2000 |
196 |
55 |
164 |
146 |
39 |
4 |
11 |
3 |
123 |
2001 |
216 |
69 |
182 |
156 |
20 |
19 |
20 |
5 |
140 |
2002 |
248 |
98 |
245 |
214 |
16 |
31 |
20 |
13 |
156 |
2003 |
175 |
87 |
186 |
153 |
35 |
29 |
14 |
10 |
128 |
2004 |
225 |
80 |
140 |
113 |
5 |
38 |
17 |
10 |
116 |
2005 |
194 |
72 |
110 |
90 |
7 |
44 |
10 |
11 |
114 |
2006 |
260 |
97 |
94 |
78 |
10 |
33 |
13 |
11 |
131 |
2007 |
289 |
114 |
109 |
79 |
4 |
47 |
11 |
11 |
157 |
2008 rev. |
324 |
169 |
149 |
115 |
7 |
36 |
5 |
11 |
167 |
2009 |
322 |
173 |
154 |
116 |
9 |
32 |
2 |
6 |
165 |
annual averages: |
|||||||||
2003-2007 |
229 |
90 |
128 |
103 |
12 |
38 |
13 |
11 |
129 |
2005-2009 |
278 |
125 |
123 |
96 |
7 |
38 |
8 |
10 |
147 |
1. More than one drug may be
reported per death. These are mentions of each drug, and should not
be added to give total deaths.
Up to 2007, some pathologists reported only those drugs which they
thought caused, or contributed to, the death
From 2008, pathologists report separately (a) drugs which were
implicated in, or which potentially contributed to the cause of
death and (b) other drugs which were present but which were not
considered to have had any direct contribution to the death
The figures for 2008 onwards are on the first basis - i.e.
basis (a) - which is now the standard basis for GROS's figures for
individual drugs. The figures for 2008 have been revised from those
published in the previous edition.
There may be other differences between years and/or areas in
the way in which the information was produced - see Section
2.
2. See paragraph 3.3.1 of commentary.